Medpace (MEDP)
(Delayed Data from NSDQ)
$423.09 USD
-4.11 (-0.96%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $423.39 +0.30 (0.07%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MEDP 423.09 -4.11(-0.96%)
Will MEDP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MEDP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MEDP
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
MEDP: What are Zacks experts saying now?
Zacks Private Portfolio Services
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands
Other News for MEDP
Sarepta upgraded, Tapestry downgraded: Wall Street's top analyst calls
Uber To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday
MEDP: UBS Downgrades Medpace Holdings, Raises Price Target | MEDP Stock News
Medpace just downgraded at UBS, here's why
UBS Downgrades Medpace (MEDP) Citing Overambitious Targets